Valuation: Natera, Inc.

Capitalization 29.44B 24.99B 22.9B 21.75B 40.19B 2,738B 41.05B 269B 106B 1,321B 110B 108B 4,669B P/E ratio 2026 *
-113x
P/E ratio 2027 * -333x
Enterprise value 28.45B 24.14B 22.13B 21.01B 38.83B 2,646B 39.66B 260B 102B 1,277B 107B 104B 4,511B EV / Sales 2026 *
10.7x
EV / Sales 2027 * 8.84x
Free-Float
96.31%
Yield 2026 *
-
Yield 2027 * -
1 day-0.32%
1 week+2.89%
Current month+3.88%
1 month+6.38%
3 months-11.54%
6 months+10.15%
Current year-9.32%
1 week 194.29
Extreme 194.29
219.46
1 month 181
Extreme 181
220
Current year 181
Extreme 181
256.36
1 year 131.81
Extreme 131.8106
256.36
3 years 36.9
Extreme 36.9
256.36
5 years 26.1
Extreme 26.1
256.36
10 years 7.35
Extreme 7.35
256.36
Manager TitleAgeSince
Chief Executive Officer 47 2019-01-01
Director of Finance/CFO 46 2017-01-31
Compliance Officer - 2017-07-31
Director TitleAgeSince
Chairman 53 2015-04-30
Director/Board Member 53 2006-12-31
Director/Board Member 47 2019-01-01
Change 5d. change 1-year change 3-years change Capi.($)
-0.32%+2.89%+40.29%+283.00% 29.54B
-0.71%+0.47%-19.36%-44.33% 7.3B
-4.21%+2.88%+16.21%+110.82% 4.69B
+1.18%+2.81%+4.54%+49.09% 2.53B
+5.69%+14.32%-26.98%+606.02% 1.93B
+1.62%+4.89%-2.81%-67.84% 1.85B
+1.28%-3.36%+35.72%+22.99% 1.82B
+2.41%+5.84%+42.88%-33.20% 1.71B
+0.08%+3.34%-1.66%+171.28% 1.14B
-1.10%+0.06%+18.01%+16.03% 1.1B
Average +0.59%+3.50%+10.68%+111.39% 5.36B
Weighted average by Cap. -0.22%+3.52%+23.04%+185.06%

Financials

2026 *2027 *
Net sales 2.67B 2.27B 2.08B 1.97B 3.64B 248B 3.72B 24.37B 9.58B 120B 10.02B 9.81B 423B 3.19B 2.71B 2.48B 2.36B 4.36B 297B 4.45B 29.14B 11.46B 143B 11.98B 11.73B 506B
Net income -249M -212M -194M -184M -340M -23.18B -348M -2.27B -895M -11.19B -935M -916M -39.53B -58.92M -50M -45.83M -43.52M -80.43M -5.48B -82.15M -538M -211M -2.64B -221M -216M -9.34B
Net Debt -995M -845M -774M -735M -1.36B -92.57B -1.39B -9.08B -3.57B -44.66B -3.73B -3.66B -158B -1.23B -1.04B -958M -909M -1.68B -114B -1.72B -11.23B -4.42B -55.24B -4.62B -4.52B -195B
Logo Natera, Inc.
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
Employees
6,138
Date Price Change Volume
26-04-20 207.74 $ -0.32% 824,538
26-04-17 208.40 $ +6.27% 1,427,090
26-04-16 196.11 $ -5.35% 1,849,023
26-04-15 207.19 $ -3.47% 1,381,774
26-04-14 214.64 $ +6.31% 1,734,420
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
207.74USD
Average target price
257.95USD
Spread / Average Target
+24.17%

Quarterly revenue - Rate of surprise